OOIR: Observatory of International Research

Papers

(The TQCC of European Heart Journal-Cardiovascular Pharmacotherapy is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	76
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	64
Early initiation of SGLT2 inhibitors after acute myocardial infarction	61
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	55
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can’t we see the evidence?	51
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	41
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	40
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	40
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	38
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	37
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis	34
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective	31
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	31
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient	31
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	30
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	30
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	29
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives	28
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	28
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	27
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	27
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy	26
All about clinical trials	23
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	23
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease	22

New ways of mitigating aldosterone in cardiorenal disease	22
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	22
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis	21
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data	21
Long-term antiplatelet monotherapy after PCI: searching for the smart choice	21
Late breaking clinical trials at ACC 22	21
Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease	20
Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization	20
Cardiovascular prevention and risk factors	20
De-escalation versus shortening of dual antiplatelet therapy	20
Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on 1-year mortality in acute coronary syndrome patients	19
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-	19
Authors’ reply to: ‘preventing atrial fibrillation with SGLT2 inhibitors: time, sex, and substrate’ by Karakasis et al.	19
News in cardiovascular pharmacotherapy from the ACC.24 Meeting	18
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic	18
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!	17
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry	16
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial	16
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis	16
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results	16
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies	15
Reply to ‘Sacubitril/valsartan in heart failure: a critical look at dementia risk and future study pathways’	15
Photoinduced skin reactions of cardiovascular drugs—a systematic review	15
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts	15
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials	15
Entering a new era of antiplatelet therapy: the 4D-ACS trial	15
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023	15
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry	14
Are NOACs always the best strategy in elderly AF patients?	14
Effects of renin–angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation	14
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: apost hocanalysis of the ATHENA trial	14
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis	14
Focus on different aspects of atrial fibrillation	14
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes	13
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis	13
Seeking for the boundaries of de-escalation in antiplatelet therapy for acute coronary syndrome	13
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study	13
What's new in pharmacotherapy at ESC Congress 2023?	13
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022	13
Different aspects of pharmacological heart failure treatment	13
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation	13
An old drug in a new era: digitoxin in the spotlight after DIGIT-HF	12
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis	12
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr	12
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials	12
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?	12
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials	12
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue	12
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?	12
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm	11

Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry	11
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial	11
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study	11
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark	11
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy	11
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study	10
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease	10
RNA-targeted therapeutics in cardiovascular disease: the time is now	10
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure	10
FLOW trial stopped early due to evidence of renal protection with semaglutide	10
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists	10
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study	10
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial	10
Response to—Current evidence and future perspective for the management of left sided prosthetic valve thrombosis	9
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies	9
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study	9
The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation	9
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study	9
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding	9
News in cardiovascular pharmacotherapy from the ACC.25 Meeting	9
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study	9